MARKET WIREYahoo Finance • 1d ago
Nuvation Bio And 2 Penny Stocks To WatchYahoo Finance report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
Why NUVB Stock dropped -3.57% Today — RQD Quant Desk Flash
$4.59 -3.57% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.55
Nuvation Bio Inc. (Class A) (NUVB) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $1.61B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NUVB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NUVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Nuvation Bio Inc. (Class A) (NYSE: NUVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.59 (-3.57% 1D, market cap $1.61B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NUVB ranks #989 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NUVB compare to RARE and ANIP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NUVB carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RARE (Ultragenyx Pharmaceutical Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B) and ANIP (ANI Pharmaceuticals Inc.) posts a C grade (63/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.62B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NUVB?
▼
Per NUVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001811063), Nuvation Bio Inc. (Class A) generated $62.9M in revenue (+699.0% YoY), -$204.6M in net income, and -$173.4M in free cash flow against $594.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.55 (-0.83%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUVB)Realized 20D OHLCV Swing Band: ±10.1%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY NUVB SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (42% of score)
Altman Z-Score 0.76 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+4/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.68+3.6% Next Q
27
Q2 (-2Q)Grade E$4.85-5.4% Next Q
24
Q3 (-1Q)Grade E$4.59+0% Next Q
22
CurrentGrade E$4.59-12% Hist 90D α
19
Trajectory: E (27) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NUVB Turnaround Squeeze
While NUVB currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.50) and Max Pain ($4.82) forces dealer call-delta covering toward $10.24.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUVB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NUVB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NUVB Stock dropped -3.57% Today — RQD Quant Desk Flash
Nuvation Bio Inc. (Class A) (NUVB) dropped -3.57% to $4.59, trading at 11% of its 52-week range ($3.92 – $9.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($3.92 – $9.75) with RSI-14 at 37.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.1% around $4.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NUVB Headlines & Catalysts
CATALYSTStocktwits • 1d ago
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer DrugStocktwits report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.debelegger.nl • 1d ago
Nuvation Bio (NUVB) Stock Price, Chart & Analysiswww.debelegger.nl report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
CATALYSTkalkine.ca • 2d ago
Is Nuvation Bio (NYSE:NUVB) Penny Stock Gaining 6% While Investors Overlook a 556% Jump in Quarterly Revenue?kalkine.ca report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 2d ago
Is Nuvation Bio (NUVB) Undervalued Following Its Phase III Safusidenib Milestone?Simply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 2d ago
3 Penny Stocks With Revenue Growth Up To 60%Simply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 2d ago
Nuvation Bio And 2 Other Top Penny StocksSimply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 2d ago
Nuvation Bio (NUVB) Following SIGMA Trial Expansion Still Looks Cheap Versus Fair ValueSimply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Nuvation Bio To Present Updated Data From Its Phase 2 J201 Trial, Three Posters On Ongoing Studies Of Safusidenib At Society For Neuro-Oncology Annual MeetingNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additional updated results from the Phase 2 J201 study and three
RISK WATCHYahoo • 5d ago
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesNuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the pivotal Phase 3 SIGMA (G203; NCT05303519) study of investigation
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NUVB)
- ✓Walkthrough of NUVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NUVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.97%📐 HORIZONTAL RANGE
2026-11-04O $4.76H $4.76L $4.59C $4.59VOL 3.72M
RES: $8.94SUP: $4.18SMA50: $5.50SMA200: $5.38
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NUVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +699.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on NUVB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NUVB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUVB)
Health Care Rank #989 of 1015
⚔️ RARE vs NUVB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NUVB vs. RARE, ANIP, QURE, KLRA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Nuvation Bio Inc. (Class A) (NUVB) ranks #989 by composite RQD confidence (19/100, grade E) and #286 by equity capitalization ($1.61B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with NUVB at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NUVB
ACTIVE
Nuvation Bio Inc. (Class A) | E | 19/100 | — | — | -35.0% | -3.57% | $1.61B | Benchmark Subject |
| RARE Ultragenyx Pharmaceutical Inc. | E | 23/100 | — | — | -35.0% | +1.24% | $1.61B | /rare-vs-nuvb → |
| ANIP ANI Pharmaceuticals Inc. | C | 63/100 | 21.5x | — | 16.0% | -1.85% | $1.62B | /anip-vs-nuvb → |
| QURE uniQure N.V. | D- | 38/100 | — | — | -35.0% | -7.49% | $1.59B | /qure-vs-nuvb → |
| KLRA Kailera Therapeutics Inc. | D | 45/100 | — | — | — | -5.52% | $1.58B | /klra-vs-nuvb → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001811063 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvation Bio Inc. (Class A) (NUVB) reported GAAP revenue of $62.9M (+699.0% vs. FY2024 revenue of $7.9M , and -77.5% cumulative change since FY2023) , GAAP net income of -$204.6M, operating cash flow of -$173.4M, and free cash flow of -$173.4M (-33.0% YoY). On the balance sheet, NUVB closed FY2025 with $594.8M in total assets against $0 in total debt (Altman Z-Score: 0.76, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $62.9M | -$204.6M | -$173.4M | -$173.4M | $594.8M | — |
| FY2024 (FY) | 2024-12-31 | $7.9M | -$567.9M | -$130.4M | -$130.4M | $540.6M | — |
| FY2023 (FY) | 2023-12-31 | $279.5M | -$75.8M | -$68.0M | -$68.0M | — | — |
3. NUVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NUVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Nuvation Bio Inc. (Class A) (NYSE: NUVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $4.59 (-3.57% 1D, market cap $1.61B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NUVB ranks #989 in composite RQD confidence.
How does NUVB compare to RARE and ANIP in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NUVB carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RARE (Ultragenyx Pharmaceutical Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B) and ANIP (ANI Pharmaceuticals Inc.) posts a C grade (63/100 RQD, P/E 21.5x, ROIC 16.0%, cap $1.62B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NUVB?
Per NUVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001811063), Nuvation Bio Inc. (Class A) generated $62.9M in revenue (+699.0% YoY), -$204.6M in net income, and -$173.4M in free cash flow against $594.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NUVB trading relative to its 50-day, 200-day, and 52-week technical levels?
NUVB last traded at $4.59 (-3.57% on volume of 3,723,554 shares), positioning the stock -16.55% below its 50-day simple moving average ($5.50) and -14.68% below its 200-day simple moving average ($5.38). Across its 52-week range of $3.92 to $9.75, NUVB sits at the 11.5% percentile with a 14-day RSI of 37.4 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($4.13 to $5.05).
ROARABLE RATING BRIEF • RQD 19/100 (E)
✓ SEC XBRL & RQD VERIFIED
NUVB — Nuvation Bio Inc. (Class A): What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Nuvation Bio Inc. (Class A) (NUVB) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.59 (-3.57% 1D, market capitalization $1.61B).
- Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -10.35%.
- Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.76, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Nuvation Bio Inc. (Class A) is a NYSE-listed issuer classified in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The company reports FY 2025 revenue of $62.9M which is a material increase from $7.9M in FY 2024..7B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nuvation Bio Inc. (Class A) (NUVB) reported $62.9M in annual revenue (up from $7.9M in FY2024, +699.0% YoY) and -$204.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($279.5M revenue, -$75.8M net income) through FY2025, NUVB scaled operating cash flow to -$173.4M and free cash flow to -$173.4M, backed by $594.8M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.35% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $3.92 – $9.75 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. An investor should note that the absence of graph data is a gap in the analysis, not evidence of an absence of dependencies. The sector (Health Care) and industry (Biotechnology: Pharmaceutical Preparations) classifications are the only structural context available.
- Key Question #1: Can NUVB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $62.9M and free cash flow of -$173.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is NUVB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
NUVB Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Nuvation Bio Inc. (Class A) (NUVB) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 1d ago
Nuvation Bio And 2 Penny Stocks To Watch Yahoo Finance report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Stocktwits • 1d ago
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug Stocktwits report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.debelegger.nl • 1d ago
Nuvation Bio (NUVB) Stock Price, Chart & Analysis www.debelegger.nl report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST kalkine.ca • 2d ago
Is Nuvation Bio (NYSE:NUVB) Penny Stock Gaining 6% While Investors Overlook a 556% Jump in Quarterly Revenue? kalkine.ca report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 2d ago
Is Nuvation Bio (NUVB) Undervalued Following Its Phase III Safusidenib Milestone? Simply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 2d ago
3 Penny Stocks With Revenue Growth Up To 60% Simply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 2d ago
Nuvation Bio And 2 Other Top Penny Stocks Simply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 2d ago
Nuvation Bio (NUVB) Following SIGMA Trial Expansion Still Looks Cheap Versus Fair Value Simply Wall St report covering Nuvation Bio Inc. (Class A) (NUVB) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
NUVB Bull vs. Bear Conversation Board — What's Your Call at $4.59?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NUVB 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $5.71 (+20.0%)
📌 Pinned Debate Recent headlines reference a Phase III safusidenib milestone and a RBC-cited brain-cancer opportunity, and FY 2025 revenue rose to $62.
Long NUVB at $4.76 targeting $5.71. Recent headlines reference a Phase III safusidenib milestone and a RBC-cited brain-cancer opportunity, and FY 2025 revenue rose to $62.9M from $7.9M.. Institutional whale score is 4/20 and the risk/reward vs. the $3.92 52-week low is skewed heavily in favor of bulls.
EarningsSniper 🐂 BULL
@CreditSpread_Watch Shorting a 4/20 institutional whale-flow stock at $4.76 is dangerous when funds are rotating into Health Care.
CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH
🎯 Target: $3.62 (-23.9%)
Spot @ $4.76 ROIC of -35%, FCF yield of -10.35%, and an Altman Z-Score of 0.76 indicate the business is consuming capital and sits in a financial-di
Here is the bear case nobody on the bull side wants to address on NUVB: ROIC of -35%, FCF yield of -10.35%, and an Altman Z-Score of 0.76 indicate the business is consuming capital and sits in a financial-distress zone.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.